NCT03805594View on ClinicalTrials.gov

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 10, 2019

Primary Completion Date

January 10, 2024

Study Completion Date

January 10, 2024

Conditions
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaProstate AdenocarcinomaStage IV Prostate CancerStage IVA Prostate CancerStage IVB Prostate Cancer
Interventions
DRUG

Lutetium Lu 177-PSMA-617

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Prostate Cancer Foundation

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, San Francisco

OTHER

NCT03805594 - 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter